CTLA4 and infection: We separately targeted Treg cells by treating Advax3- plus Bl-Eng2-vaccinated mice with anti-CD25 monoclonal antibody (MAb) at days −7 and −4 of infection and anti-CTLA4 MAb at the time of infection and weekly thereafter as described previously (21) and measured cellular responses and survival.